Kalaris TherapeuticsKLRS
那斯達克 · USD
10.20
-0.22
(-2.11%)
盤中 12/19 11:15 (UTC+8)
12/19 11:15 (UTC+8)
Kalaris TherapeuticsKLRS
10.20
-0.22
(-2.11%)
財務數據
損益表
- 0.00
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- 營業收入(億)
- 季增長率(%)
單位：美元千元
2025/Q3 | 2025/Q2 | 2025/Q1 | 2024/Q4 | 2024/Q3 | 2024/Q2 | 2024/Q1 | 2023/Q4 | |
營業收入淨額 | - | - | - | - | - | - | - | 0 |
營業成本 | - | - | - | - | - | - | - | - |
營業毛利 | - | - | - | - | - | - | - | 0 |
營業費用 | 12,741 | 12,256 | - | 20,842 | 39,041 | 37,508 | 32,299 | 3,464 |
研發費用 | 9,126 | 8,440 | 6,030 | -28,852 | 6,848 | 10,305 | 12,173 | 2,966 |
推銷及管理費用 | 3,615 | 3,816 | 4,324 | 39,509 | 22,134 | 17,227 | 10,662 | 498 |
非經常性項目費用 | - | - | - | 10,185 | 10,059 | 9,976 | 9,464 | - |
其他營業費用 | - | - | - | - | - | - | - | - |
營業利益 | -12,741 | -12,256 | -10,354 | -20,842 | -39,041 | -37,508 | -32,299 | -3,464 |
其他收入及費用 | 847 | 906 | 1,601 | 7,822 | 7,020 | 4,462 | 2,000 | - |
利息費用 | - | - | 1,443 | -1,392 | -577 | -78 | - | 39 |
稅前純益 | -11,894 | -11,350 | -10,196 | -11,628 | -31,444 | -32,968 | -30,299 | -3,471 |
所得稅 | - | - | - | - | - | - | - | - |
稅後純益 | -11,894 | -11,350 | -10,196 | -11,628 | -31,444 | -32,968 | -30,299 | -3,471 |
基本每股稅後盈餘(元) | -0.64 | -0.61 | -2.52 | - | -28.16 | -4.18 | -0.18 | - |
稀釋每股稅後盈餘(元) | -0.52 | -0.61 | -2.52 | 23.71 | -28.57 | -4.76 | -2.60 | -12.19 |
基本平均股數(千股) | 18701.00 | 18701.00 | 4053.00 | - | 1352.00 | 1352.00 | 18702.00 | - |
稀釋平均股數(千股) | 18701.00 | 18701.00 | 4053.00 | - | 1352.00 | 1352.00 | 18702.00 | - |
還原基本每股稅後盈餘(元) | -0.64 | -0.61 | -2.52 | - | -28.16 | -4.18 | -0.18 | - |
還原稀釋每股稅後盈餘(元) | -0.52 | -0.61 | -2.52 | 23.71 | -28.57 | -4.76 | -2.60 | -12.19 |
還原基本平均股數(千股) | 18,701 | 18,701 | 4,053 | - | 1,352 | 1,352 | 18,702 | - |
還原稀釋平均股數(千股) | 18,701 | 18,701 | 4,053 | - | 1,352 | 1,352 | 18,702 | - |
EBITDA(千元) | -11,974 | -11,350 | -8,753 | -14,271 | -33,266 | -34,173 | -31,044 | -3,432 |